PLxGuard Development Pipeline

Product Candidate Pre-Clinical Phase 1 Phase 2 Phase 3 Status
Aspertec 325mg

 

FDA Approved*
Aspertec 81mg

 

sNDA may be filed in 2017
PL1200 Ibuprofen 200mg

 

GI safer clinical proof of concept demonstrated
PL1100 Ibuprofen 400mg

 

GI safer clinical proof of concept demonstrated
PL5100 Diclofenac 50mg

 

GI safer preclinical proof of concept demonstrated
PL4100 Indomethacin

 

GI safer preclinical proof of concept demonstrated

OTC: Over-The-Counter, Rx: Prescription, sNDA: Supplemental New Drug Application

*FDA approval subject to final label